CTLA4 and hypophysitis: Data from early trials have described that anti‐CTLA4‐related irAEs might be associated with clinical benefit.176, 177 A pooled analysis of 343 patients treated with ipilimumab showed that there was a trend toward superior disease control in patients with at least grade 2 irAEs when compared withthose with grade 1 irAEs.177 Patients with hypophysitis had a prolonged median survival time compared with those without hypophysitis following CTLA‐4 inhibitor therapy.176 Thus, anti‐CTLA‐4‐associated pituitary‐adrenal dysfunction might be suggestive of benefit rather than harm in certain conditions.